MEDP|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.44 | - | - |
| Q2'26 | $4.05 | $4.25 | +4.9% |
| Q4'25 | $4.23 | $4.67 | +10.5% |
| Q4'24 | $3.12 | $3.68 | +18.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $729M | - | - |
| Q2'26 | $701M | $707M | +0.8% |
| Q4'25 | $691M | $708M | +2.5% |
| Q4'24 | - | $537M | - |
Market Data
MEDP Stock Snapshot
MEDP is currently trading at $590.67, giving Medpace Holdings, Inc. a market cap of 16.35B and a P/E ratio of 33.3. Today's range spans $582.08–$594.99, with shares opening at $590.45 and moving up $0.33 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 64/100.
Over the past year MEDP has traded between $373.00 and $677.90 - the current price is +58.4% off the 52-week low and -12.9% from the high.
In the Healthcare peer group, Medpace Holdings, Inc. (MEDP) stands out for a BUY signal backed by aligned sentiment - score 86/100, sentiment bullish at 64/100, price $590.67 (in the upper portion of its 52-week range). (P/E: 33.3) With 16.35B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $373.00–$677.90 shows the stock has already proven it can make significant moves.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (64/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $590.67 (in the upper portion of its 52-week range), MEDP's position within the $373.00–$677.90 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Understanding Why Investors Hold Medpace (MEDP) (MEDP)
Medpace Holdings, Inc. (MEDP) is a leading provider of clinical research services, specializing in drug and medical device development across various therapeutic areas. The company's comprehensive services span the entire clinical trial process, from Phase I to Phase IV, supporting pharmaceutical, biotechnology, and medical device companies globally. Medpace's integrated approach, including project management, data analysis, and regulatory affairs, positions it as a critical partner in the development of new medical treatments.
The investment case for Medpace is built upon its strong financial performance and consistent revenue growth, driven by the increasing demand for clinical research services. The company's ability to exceed earnings and revenue expectations in recent quarters highlights its operational efficiency and market leadership. Furthermore, Medpace's focus on innovation and its broad service offerings contribute to its competitive advantage within the healthcare sector.
Portfolio decisions around Medpace stock should consider the company's growth trajectory, margin performance, and the broader industry outlook. Investors should carefully evaluate management's guidance and commentary on earnings calls to assess the sustainability of the current momentum. Analyzing Medpace's ability to maintain its growth while addressing potential margin pressures is crucial for informed investment decisions.
Strong Growth
Medpace has demonstrated robust year-over-year growth, particularly in revenue, driven by increasing demand for clinical research services.
The company consistently outperforms EPS and revenue estimates, showcasing its operational efficiency and market leadership.
This growth is supported by a comprehensive suite of services and a focus on innovation within the healthcare sector.
Industry Position
Medpace operates within the Diagnostics & Research industry, a sector experiencing significant growth due to advancements in medical treatments.
The company provides services across the entire clinical trial process, from Phase I to Phase IV, positioning it as a critical partner.
Medpace's global presence and diverse service offerings contribute to its competitive advantage in the market.
Financial Performance
Medpace's recent financial results, including Q4 2025, show significant revenue growth and strong EPS performance.
The company consistently beats estimates, indicating effective management and operational excellence.
Investors should monitor margin performance and the sustainability of the current momentum.
Market Dynamics
The market reaction to Medpace's strong Q4 results was mixed, with the stock price declining despite exceeding expectations.
This may be due to concerns about margin performance and 2026 guidance, which investors should monitor closely.
Understanding market dynamics and investor sentiment is crucial for making informed investment decisions.
Management Outlook
Investors should closely monitor management's commentary on the upcoming earnings call for insights into future performance.
The market will likely focus on the company's ability to maintain its growth trajectory and address any margin pressures.
Any shifts in guidance or commentary on the broader industry outlook should be carefully considered.
Valuation Metrics
Medpace's P/E ratio is currently at 26.4703, which should be evaluated relative to industry peers and historical averages.
The company's market capitalization is approximately $11.94 billion, reflecting its significant presence in the market.
Analyzing valuation metrics alongside growth prospects provides a comprehensive view of the investment potential.
Positioning MEDP
Medpace shares can be considered for a growth-oriented portfolio, given its strong financial performance and industry position. Exposure should increase when the company demonstrates continued revenue growth and maintains or improves its margins. Conversely, investors should reduce exposure if there are significant declines in revenue growth or if margin pressures persist, as indicated by management guidance.
Risk Factors
Medpace faces risks inherent to the clinical research industry, including regulatory changes and competitive pressures. These factors can impact project timelines, profitability, and overall growth. Investors should consider these risks when evaluating the company's long-term prospects.
- Clinical Trial Delays
Medpace's revenue depends on the timely execution of clinical trials. Delays due to patient recruitment challenges, regulatory hurdles, or unforeseen clinical trial results can significantly impact project timelines and revenue recognition. This risk is amplified if trials are in competitive therapeutic areas or face increased scrutiny from regulatory bodies.
- Competition Intensification
The clinical research market is highly competitive, with numerous CROs vying for contracts. Increased competition, particularly from larger or more specialized firms, could lead to pricing pressures and reduced profit margins for Medpace. This risk is heightened if competitors offer more attractive pricing or broader service offerings.
- Regulatory Changes
Changes in regulations governing clinical trials, such as stricter data requirements or new approval processes, could increase costs and complexity for Medpace's clients. This could lead to decreased demand for services or require significant investments in compliance. The risk is more pronounced in regions with evolving regulatory landscapes.
- Client Concentration
Medpace's financial performance may be significantly impacted by the loss or reduction of business from major clients. A decline in spending by key pharmaceutical or biotech companies could lead to a substantial decrease in revenue and profitability. This risk is exacerbated if Medpace's client base is not sufficiently diversified.
- Labor Market Challenges
The success of Medpace relies on its ability to attract and retain qualified clinical research professionals. Difficulty in recruiting or retaining skilled personnel, such as clinical monitors and data analysts, could lead to project delays and increased labor costs. This risk is heightened during periods of high industry demand for specialized talent.
- Margin Pressure
Medpace's profitability is sensitive to fluctuations in project costs, including labor, materials, and overhead. Unexpected increases in these costs, or unfavorable contract terms, could lead to margin compression. This risk is intensified by inflationary pressures or changes in the mix of services offered.
MEDP Competitive Positioning
Medpace Holdings, Inc. (MEDP) is tracked alongside these names in Diagnostics & Research on DailyIQ.
What Moves MEDP Stock?
Medpace Holdings, Inc. stock price is primarily driven by its ability to secure and execute clinical research contracts within the pharmaceutical and medical device industries. The company's financial performance is closely tied to its success in winning new business and efficiently managing ongoing clinical trials.
Clinical Trial Wins
Medpace's revenue growth is directly linked to the number and size of clinical trials it secures from pharmaceutical and biotech clients. Winning new contracts, especially for Phase II and III trials, fuels revenue expansion.
Increased contract wins typically lead to higher revenue and earnings, positively impacting the stock price. Conversely, a slowdown in new contract acquisition can signal potential revenue deceleration and negatively affect the stock.
R&D Spending Trends
The overall level of R&D spending by pharmaceutical and biotech companies significantly influences demand for Medpace's services. Increased industry R&D investment translates into more clinical trials and higher demand for Medpace's offerings.
Positive trends in industry R&D spending often correlate with increased revenue and profitability for Medpace, which can lead to a higher stock valuation. Conversely, a decline in R&D spending can pressure the company's growth prospects.
Operational Efficiency
Medpace's ability to manage clinical trials efficiently, controlling costs and timelines, is crucial for profitability. Effective project management, data analysis, and regulatory compliance are key drivers of operational success.
Efficient operations and strong project execution lead to improved margins and profitability, which can boost investor confidence and drive the stock price higher. Conversely, operational challenges or delays can negatively impact financial results and stock performance.
Key insight: The most important factor influencing Medpace's stock price is its ability to consistently secure new clinical trial contracts and efficiently manage its existing portfolio, directly impacting revenue growth and profitability.
Key Metrics for MEDP
Medpace's success hinges on its ability to secure and execute clinical trials. Tracking key metrics helps gauge its growth potential and profitability. These metrics offer insights into the company's operational efficiency and market position.
Backlog Growth: Measures the value of future clinical trial work under contract. Increasing backlog indicates strong demand for Medpace's services and future revenue. Declining backlog suggests potential slowdown. It directly impacts revenue and stock price.
Revenue Growth: Reflects the increase in revenue from clinical trial services. Consistent, robust growth shows Medpace's ability to win and execute projects. Slowing growth raises concerns. It's a key indicator of the company's overall health and market share.
Gross Margin: Indicates the profitability of Medpace's services after direct costs. Expanding margins show efficient project execution and pricing power. Contracting margins may signal cost pressures. It directly affects the company's bottom line and investor confidence.
New Awards: Represents the value of new clinical trial contracts won. A rising trend reveals Medpace's success in securing new business. A decline suggests challenges in the competitive landscape. It's a leading indicator of future revenue growth.
Project Cancellation Rate: Measures the percentage of clinical trial projects terminated before completion. A low rate indicates strong client satisfaction and project execution. A high rate suggests operational issues. It impacts revenue and profitability for Medpace.
SG&A as % Revenue: Shows selling, general, and administrative expenses relative to revenue. A decreasing percentage suggests improved operational leverage. An increasing percentage may indicate rising costs. It impacts Medpace's profitability and valuation.
Frequently Asked Questions About MEDP
Is Medpace Holdings (MEDP) stock a good investment?
Whether Medpace (MEDP) is a good investment depends on its ability to sustain growth in the competitive clinical research market. The company's strong historical performance and focus on drug and medical device development services are key factors. Investors should evaluate the company's ability to manage margins and maintain its growth trajectory.
What drives the stock price of Medpace Holdings (MEDP)?
The stock price of MEDP is primarily driven by revenue growth, earnings per share (EPS), and the company's ability to secure new contracts. Market sentiment towards the healthcare sector and the clinical research industry also plays a significant role. Investors should monitor Medpace's financial results and industry trends.
Does Medpace (MEDP) pay a dividend?
Medpace (MEDP) does not currently pay a dividend. The company has historically focused on reinvesting earnings to fuel growth and expand its service offerings. Investors seeking dividend income should consider other investment options.
What are the risks of investing in Medpace (MEDP)?
Investing in Medpace (MEDP) carries risks, including competition within the clinical research industry and potential margin pressures. Economic downturns and changes in the pharmaceutical and biotechnology sectors can also impact performance. Investors should assess these risks before investing.
What is Medpace Holdings' (MEDP) investment thesis?
The investment thesis for Medpace (MEDP) centers on its growth potential in the clinical research market. The company's focus on providing services from Phase I to Phase IV clinical trials and its strong historical performance support this thesis. Investors should consider the company's ability to maintain its growth trajectory and manage its margins.
How does Medpace (MEDP) compare to its competitors?
Medpace (MEDP) competes with other clinical research organizations (CROs) in the healthcare sector. Investors should compare Medpace's financial performance, growth rates, and service offerings against its competitors. Key metrics include revenue growth, profitability, and market share.
What is the valuation of Medpace (MEDP) stock?
The valuation of Medpace (MEDP) stock can be assessed using metrics like the price-to-earnings (P/E) ratio and market capitalization. Investors should compare these metrics to industry averages and historical data. The current P/E ratio is 26.4703, which should be considered in the context of the company's growth prospects.
What are the growth prospects for Medpace Holdings (MEDP)?
Medpace's (MEDP) growth prospects depend on the expansion of the clinical research market and its ability to secure new contracts. The company's focus on drug and medical device development services supports its growth potential. Investors should monitor the company's revenue growth and expansion plans.
What is Medpace's (MEDP) strategy for future growth?
Medpace's (MEDP) strategy for future growth likely involves expanding its service offerings and geographic reach. The company may also focus on securing new contracts with pharmaceutical and biotechnology companies. Investors should watch for any strategic initiatives announced by the company.
How has Medpace (MEDP) performed recently?
Medpace (MEDP) has shown strong recent performance, with significant revenue growth and EPS exceeding expectations in the last two reported quarters. However, the market reaction to the strong Q4 results was mixed. Investors should review the company's earnings reports and management commentary.
What are the key factors influencing Medpace (MEDP)'s stock price?
Key factors influencing Medpace (MEDP)'s stock price include revenue growth, earnings per share (EPS), and the company's ability to secure new contracts. Market sentiment towards the healthcare sector and the clinical research industry also plays a significant role. Investors should monitor Medpace's financial results and industry trends.
What should investors watch for in Medpace (MEDP)'s upcoming earnings call?
Investors should closely monitor management's commentary on the upcoming earnings call for insights into future performance and the sustainability of the current momentum. The market will likely focus on the company's ability to maintain its growth trajectory and address any concerns about margin pressures. Watch for any shifts in guidance or commentary on the broader industry outlook.
Learn More
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).